07:50 AM EDT, 07/01/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its marketing authorization application for sipavibart has been accepted by the European Medicines Agency under an accelerated assessment procedure.

Sipavibart is an investigational antibody to provide pre-exposure prophylaxis of Covid-19 in immunocompromised patients, the company said.

An accelerated assessment shortens the timeframe for the agency's Committee for Medicinal Products for Human Use to review an application.

Price: 78.14, Change: +0.15, Percent Change: +0.19